Key Highlights

  • Nexalis Therapeutics Ltd shares trade at AUD 0.015, up 66.67% during the live 25 September session.
  • The company is a clinical-stage biopharmaceutical company developing therapies for pain management and mental health conditions.
  • Recent company announcements outline the current operational work program and portfolio priorities.
  • Attention now turns to clinical-study readouts, regulatory progress across the development pipeline and the sequencing of further trial activity.

Nexalis Therapeutics Ltd (ASX:NX1) is trading higher during the live Australian market session on 25 September 2026, with the stock at AUD 0.015, up 66.67%. The move has placed Nexalis Therapeutics among the day’s notable gainers.

Operationally, Nexalis Therapeutics is a clinical-stage biopharmaceutical company developing therapies for pain management and mental health conditions. Its development portfolio includes IRX-211, an inhaled treatment being advanced for breakthrough cancer pain, IRX-616a for panic disorder and SRX-25, an oral esketamine-based program. During 2026, the company reported clinical activity across its pipeline, including completion of dosing in the Phase 1 IRX-616a study and continued work around its clinical programs.

Company Business

Nexalis Therapeutics is a clinical-stage biopharmaceutical company developing therapies for pain management and mental health conditions. Its activities are centred on the assets, products or development programs described in its company announcements and corporate releases. The Business remains at a stage where execution against stated work programs is important to how its portfolio develops. For investors following ASX:NX1, the operational picture is therefore best assessed through project progress, funding capacity, regulatory or technical milestones and the company’s formal reporting rather than day-to-day share-price movements.

Latest Operational Picture

Its development portfolio includes IRX-211, an inhaled treatment being advanced for breakthrough cancer pain, IRX-616a for panic disorder and SRX-25, an oral esketamine-based program. During 2026, the company reported clinical activity across its pipeline, including completion of dosing in the Phase 1 IRX-616a study and continued work around its clinical programs. These developments form the current backdrop to the company’s work program. The company’s next operational steps will depend on the timetable attached to its projects and the outcomes of technical, commercial, regulatory or customer-facing work, as applicable.

Sector Context

Healthcare development companies typically move through pre-clinical work, clinical trials, regulatory review and commercial preparation. Trial outcomes, study timing, funding and regulatory decisions can materially affect development schedules. Company-specific announcements remain the primary reference point for assessing how those sector factors are affecting the business at a given time.

Risks to Consider

Clinical-stage biotechnology carries trial, regulatory, funding and development risks. A candidate may not meet study objectives, timelines can change and further Capital may be required before commercialisation. Investors also need to consider Liquidity and funding conditions where relevant to the company’s size and stage of development.

What to Watch Next

The next areas to monitor are clinical-study readouts, regulatory progress across the development pipeline and the sequencing of further trial activity. Further company announcements will provide the clearest indication of how these work streams are progressing. With ASX:NX1 trading at AUD 0.015 during the 25 September session, the immediate market snapshot is distinct from the longer-term operational pathway. Future assessment will depend on disclosed milestones and the company’s execution against its stated plans.